ClinicalTrials.gg

Program

elacestrant

Also written as “Elacestrant”, “RAD1901” and “Elacestrant dihydrochloride”.

Its studies are mostly in Breast Neoplasms · Hot Flashes, led by 3 companies.

Furthest: phase 3, since Dec 3, 201812 company-led studies, 5 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Menarini Group95 open or runningphase 3since Dec 3, 2018Dec 31, 2014Nov 2026phase 2 · NCT05596409
Radius Pharmaceuticals20 open or runningphase 2since Mar 6, 2009Mar 6, 2009none ahead
Criterium10 open or runningphase 2since Dec 30, 2020Dec 30, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 6, 2009First study: phase 2 study in Hot FlashesNew to Radius PharmaceuticalsRadius Pharmaceuticals · NCT00875420 · 100 enrolled · United States
  2. Dec 31, 2014Menarini Group's first study: phase 1 study in Advanced ER+, HER2-Negative Breast CancerNew to Menarini GroupMenarini Group · NCT02338349 · 57 enrolled · United States
  3. Jan 6, 2016Phase 1 study in Breast NeoplasmsMenarini Group · NCT02650817 · 16 enrolled · Belgium, Netherlands
  4. Jan 8, 2016Phase 2 study in Hot FlashesRadius Pharmaceuticals · NCT02653417 · 139 enrolled · United States
  5. Dec 3, 2018Phase 3 study in Breast NeoplasmsMenarini Group · NCT03778931 · 478 enrolled · United States, Argentina, Australia and more
  6. Dec 30, 2020Criterium's first study: phase 2 study in Breast NeoplasmsNew to CriteriumCriterium · NCT04791384 · 5 enrolled · United States
  7. May 16, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05386108 · 73 planned · United States, Belgium, France and more
  8. Sep 22, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05563220 · 435 enrolled · United States, Argentina, Australia and more
  9. Oct 24, 2022Phase 2 study in Breast NeoplasmsMenarini Group · NCT05596409 · 61 enrolled · United States, Brazil, Bulgaria and more
  10. Nov 6, 2023Phase 1 study in Breast NeoplasmsMenarini Group · NCT06126575 · 16 enrolled · United States
  11. Jul 1, 2024Phase 3 study in Breast NeoplasmsMenarini Group · NCT06492616 · 4,556 enrolled · United States, Argentina, Australia and more
  12. Aug 10, 2026Phase 2 study in Breast NeoplasmsMenarini Group · NCT07766018 · 70 planned · Japan

Ahead

  1. Nov 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05596409
  2. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05386108
  3. Dec 27, 2026Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT05563220
  4. Oct 2028Primary completion: phase 2 study in Breast NeoplasmsMenarini Group · NCT07766018

TargetBeta

ESR1 →read by rule
“An orally available, selective estrogen receptor degrader (SERD), with antineoplastic activity”NCIt, by rule
“Estrogen receptor alpha degrader; Estrogen receptor alpha degrader”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
EstradiolruleNovo Nordiskphase 469
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07766018Breast Neoplasms · Japan2RecruitingMenarini GroupOct 202870
NCT06492616Breast Neoplasms · United States, Argentina, Australia and more3Active, not recruitingMenarini GroupAug 20294,556
NCT06126575Breast Neoplasms · United States1CompletedMenarini GroupNov 11, 202416
NCT05596409Breast Neoplasms · United States, Brazil, Bulgaria and more2Active, not recruitingMenarini GroupNov 202661
NCT05563220Breast Neoplasms · United States, Argentina, Australia and more2Active, not recruitingMenarini GroupDec 27, 2026435
NCT05386108Breast Neoplasms · United States, Belgium, France and more2RecruitingMenarini GroupDec 202673
NCT04791384Breast Neoplasms · United States2TerminatedCriteriumSep 16, 20245
NCT03778931Breast Neoplasms · United States, Argentina, Australia and more3CompletedMenarini GroupAug 24, 2021478
NCT02653417Hot Flashes · United States2TerminatedRadius PharmaceuticalsDec 12, 2016139
NCT02650817Breast Neoplasms · Belgium, Netherlands1CompletedMenarini GroupAug 30, 201816
NCT02338349Advanced ER+, HER2-Negative Breast Cancer · United States1CompletedMenarini GroupSep 201957
NCT00875420Hot Flashes · United States2CompletedRadius PharmaceuticalsJan 2010100

How it is read

Names in the registry

  • “Elacestrant”, 8 entries
  • “RAD1901”, 6 entries
  • “Elacestrant dihydrochloride”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.